全文获取类型
收费全文 | 129044篇 |
免费 | 7343篇 |
国内免费 | 1125篇 |
专业分类
耳鼻咽喉 | 2006篇 |
儿科学 | 1930篇 |
妇产科学 | 1906篇 |
基础医学 | 20616篇 |
口腔科学 | 3129篇 |
临床医学 | 11957篇 |
内科学 | 23067篇 |
皮肤病学 | 4057篇 |
神经病学 | 10434篇 |
特种医学 | 7420篇 |
外科学 | 16935篇 |
综合类 | 548篇 |
现状与发展 | 3篇 |
一般理论 | 27篇 |
预防医学 | 6768篇 |
眼科学 | 3241篇 |
药学 | 11609篇 |
中国医学 | 1489篇 |
肿瘤学 | 10370篇 |
出版年
2023年 | 918篇 |
2022年 | 2786篇 |
2021年 | 4480篇 |
2020年 | 2155篇 |
2019年 | 3020篇 |
2018年 | 3738篇 |
2017年 | 3059篇 |
2016年 | 3993篇 |
2015年 | 5558篇 |
2014年 | 6580篇 |
2013年 | 7626篇 |
2012年 | 11442篇 |
2011年 | 10964篇 |
2010年 | 6286篇 |
2009年 | 5396篇 |
2008年 | 7656篇 |
2007年 | 7283篇 |
2006年 | 6548篇 |
2005年 | 6083篇 |
2004年 | 5285篇 |
2003年 | 4612篇 |
2002年 | 3976篇 |
2001年 | 3054篇 |
2000年 | 2805篇 |
1999年 | 2149篇 |
1998年 | 913篇 |
1997年 | 675篇 |
1996年 | 515篇 |
1995年 | 458篇 |
1994年 | 390篇 |
1993年 | 336篇 |
1992年 | 751篇 |
1991年 | 700篇 |
1990年 | 644篇 |
1989年 | 559篇 |
1988年 | 468篇 |
1987年 | 469篇 |
1986年 | 332篇 |
1985年 | 368篇 |
1984年 | 262篇 |
1983年 | 193篇 |
1982年 | 132篇 |
1981年 | 169篇 |
1980年 | 128篇 |
1979年 | 223篇 |
1978年 | 162篇 |
1976年 | 133篇 |
1975年 | 120篇 |
1974年 | 140篇 |
1973年 | 119篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Gwi Eon Kim Yong Bae Kim Nam Hoon Cho Hyun-Cheol Chung Hong Ryull Pyo Jong Doo Lee Tchan Kyu Park Woong Sub Koom Mison Chun Chang Ok Suh 《Clinical cancer research》2004,10(4):1366-1374
PURPOSE: To evaluate the potential of the new prognostic information gained by analyzing the coexpression of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) in cervical cancer patients. EXPERIMENTAL DESIGN: Sixty-eight patients with International Federation of Gynecology and Obstetrics stage IIB squamous cell carcinoma of the uterine cervix, who underwent concurrent chemoradiotherapy between 1993 and 1996, were divided into the following four groups according to their immunoreactivities for EGFR and COX-2 in paraffin-embedded sections: (a). the EGFR-negative/COX-2-negative group (n = 11); (b). the EGFR-negative/COX-2-positive group (n = 8); (c). the EGFR-positive/COX-2-negative group (n = 27); and (d). the EGFR-positive/COX-2-positive group (n = 22). The clinical features, patterns of treatment failure, and survival data in the four groups were compared. RESULTS: Positive immunoreactivity for EGFR and COX-2 was observed in 49 of 68 (72%) and 19 of 68 (28%), respectively. However, no strong correlation was found between the levels of EGFR and COX-2 immunopositivity (R(2) = 0.05, P = 0.07). Patients in the EGFR-positive/COX-2-positive group had a higher likelihood of locoregional recurrence than those in the other three groups (P = 0.02). Of the patients in the four groups, patients positive for both oncoproteins were found to have the worst prognosis with an overall 5-year disease-free survival rate of 55% compared with 91% for the EGFR-negative/COX-2-negative patients, 88% for the EGFR-negative/COX-2-positive patients, and 69% for the EGFR-positive/COX-2-negative patients (P = 0.05, log-rank test). In addition, the synchronous coexpression of the EGFR and COX-2 oncoproteins was found to be an independent prognostic factor by univariate and multivariate analyses (relative risk = 4.0, P = 0.03). CONCLUSIONS: Given these observations, we conclude that the coexpression of EGFR and COX-2 immunoreactivity may be used as a potent molecular risk factor for predicting the poor survival of patients with the International Federation of Gynecology and Obstetrics stage IIB squamous cell carcinoma of the uterine cervix. 相似文献
992.
993.
Terry Y Shibuya Sanghun Kim Kevin Nguyen Johnny Do Christine E McLaren Kuo-Tung Li Wen-Pin Chen Parag Parikh Ashish Wadhwa Xiaolin Zi Vincent Y Chen Hau-Sin Wong William B Armstrong George H Yoo 《Clinical cancer research》2004,10(20):7088-7099
PURPOSE: We have proposed to characterize the mechanism through which bioactive surgical sutures generate a T(H)1 immune response and to define the immune-stimulating half-life of the sutures. EXPERIMENTAL DESIGN: Bioactive sutures of interferon gamma (IFNgamma), interleukin 2 (IL-2), anti-CD3/CD28, anti-CD3/CD28 + IL-2, or anti-CD3/CD28 + IFNgamma sutures were used to stimulate lymphocytes from normal donors and from head and neck cancer patients in vitro over a 24-day period. Cell supernatants were analyzed by ELISA, and T cells were phenotyped to characterize the immune response generated. Intracellular cytokine staining was performed to measure the expansion of flu-specific T cells. Electromobility shift assay and supershift assay were used to measure the intranuclear DNA binding activity of nuclear factor kappaB and its p65 subunit in T cells activated by sutures in the presence and absence of a proteasome inhibitor, MG-132. RESULTS: Anti-CD3/CD28, anti-CD3/CD28 + IL-2, or anti-CD3/CD28 + IFNgamma generated a prolonged T(H)1 immune response for 18 days in vitro. Anti-CD3/CD28 expanded flu-specific T cells. Activated T cells demonstrated enhanced CD40 ligand (CD40L) expression within 72 hours of stimulation, which stimulated other cells to secrete IL-12. Stimulated T cells demonstrated increased intranuclear expression of nuclear factor-kappaB, which was blocked by MG-132, and also reduced CD40L and IL-12 expression. CONCLUSIONS: This is the first report to demonstrate that bioactive surgical sutures can generate a prolonged T(H)1 immune response and expand flu-specific T cells. Bioactive sutures, which are primarily a T-cell stimulant, also stimulated other cells to secrete IL-12 and prolonged the immune response. Sutures may provide a novel in situ stimulating strategy for enhancing the immune system of cancer patients. 相似文献
994.
995.
Young Ho Yun Chang Geol Lee Si-young Kim Sang-wook Lee Dae Seog Heo Jun Suk Kim Keun Seok Lee Young Seon Hong Jung Suk Lee Chang Hoon You 《Journal of clinical oncology》2004,22(2):307-314
PURPOSE:To ascertain the attitude of cancer patients and their families toward disclosure of terminal illness to the patient. PATIENTS AND METHODS: We constructed a questionnaire that included demographic and clinical information and delivered it to 758 consecutive individuals (433 cancer patients and 325 families that have a relative with cancer) at seven university hospitals and one national cancer center in Korea. RESULTS: 380 cancer patients and one member from each of 281 families that have a relative with cancer completed the questionnaire. Cancer patients were more likely than family members to believe that patients should be informed of the terminal illness (96.1% v 76.9%; P <.001). Fifty percent of the family members and 78.3% of the patients thought that the doctor in charge should be the one who informs the patient. Additionally, 71.7% of the patients and 43.6% of the family members thought that patients should be informed immediately after the diagnosis. Stepwise multiple logistic regression indicated that the patient group was more likely than the family group to want the patient to be informed of the terminal illness (odds ratio [OR], 9.76; 95% CI, 4.31 to 22.14), by the doctor (OR, 4.00; 95% CI, 2.61 to 6.11), and immediately after the diagnosis (OR, 3.64; 95% CI, 2.45 to 5.41). CONCLUSION: Our findings indicated that most cancer patients want to be informed if their illness is terminal, and physicians should realize that the patient and the family unit may differ in their attitude toward such a disclosure. Our results also reflect the importance of how information is given to the patient. 相似文献
996.
Nita L Seibel Sierra Li Norman E Breslow J Bruce Beckwith Daniel M Green Gerald M Haase Michael L Ritchey Patrick R M Thomas Paul E Grundy Jerry Z Finklestein Tae Kim Stephen J Shochat Panayotis P Kelalis Giulio J D'Angio 《Journal of clinical oncology》2004,22(3):468-473
PURPOSE: To evaluate the effect of conventional and standard (ST) versus pulse-intensive (PI) chemotherapy and short-duration versus long-duration chemotherapy on relapse-free survival (RFS) and overall survival rates of patients with clear-cell sarcoma of the kidney (CCSK) entered onto the National Wilms' Tumor Study (NWTS)-4. PATIENTS AND METHODS: The 5-year and 8-year RFS rates were determined for patients with CCSK treated on the NWTS-4. After August 6, 1986, 40 previously untreated children younger than 16 years with CCSK were randomly assigned, after the completion of 6 months of chemotherapy, to discontinue (short) or continue 9 additional months (long) of treatment with chemotherapy regimens that included vincristine and either divided-dose (ST) courses (5 days) or single-dose (PI) treatment with dactinomycin and divided-dose (ST) courses (3 days) or single-dose (PI) treatment with doxorubicin. RESULTS: For patients with CCSK, the 5- and 8-year RFS rates were 65.2% and 60.6%, respectively, for patients randomly assigned to the short chemotherapy and 87.8% (both 5- and 8-year RFS) for patients randomly assigned to the long chemotherapy (P =.08). The overall survival rates for patients at 5 and 8 years were 95.5% and 85.9%, respectively, for the short chemotherapy and 87.5% (both 5- and 8-year overall survival) for the long chemotherapy (P =.99). In NWTS-4, the overall survival rates for patients with CCSK improved from NWTS-3 (83% v 66.9% at 8 years, respectively; P <.01). CONCLUSION: CCSK patients exhibit an improved RFS from a longer course of therapy when using vincristine, doxorubicin, and dactinomycin, but their long-term survival is unchanged compared with patients receiving 6 months of therapy. The overall survival rates for patients with CCSK have improved from NWTS-3. 相似文献
997.
Sandra J Horning Edie Weller KyungMann Kim John D Earle Michael J O'Connell Thomas M Habermann John H Glick 《Journal of clinical oncology》2004,22(15):3032-3038
PURPOSE: To compare low-dose (30 Gy) radiotherapy (RT) with observation (OBS) in limited-stage aggressive lymphoma patients achieving complete remission (CR) after chemotherapy, and to measure conversion from partial response (PR) to CR with high-dose (40 Gy) RT. PATIENTS AND METHODS: From 1984 to 1992, stage I (with risk factors) and II adults with diffuse aggressive lymphoma in CR after eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) were randomly assigned to 30 Gy involved-field RT or OBS. PR patients received 40 Gy RT. RESULTS: Among 172 CR patients, the 6-year disease-free survival (DFS) was 73% for low-dose RT versus 56% for OBS (two-sided P = .05). Failure-free survival (two-sided P = .06), and time to progression (two-sided P = .06) also favored RT. Intent-to-treat analyses yielded similar results. No survival differences were observed. Three RT versus 15 OBS patients relapsed in initial disease sites. At 6 years, failure-free survival was 63% in PR patients; conversion to CR did not significantly influence clinical outcome. CONCLUSION: For patients in CR after CHOP, low-dose RT prolonged DFS and provided local control, but no survival benefit was observed. The majority of PR patients were event-free at 6 years despite residual radiographic abnormalities. Future efforts should be directed toward improved imaging and more effective systemic therapies. 相似文献
998.
Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. 总被引:16,自引:0,他引:16
Tae Won Kim Hyoungnam Lee Yoon-Koo Kang Mi Sun Choe Min-Hee Ryu Heung Moon Chang Jung Sun Kim Jeong Hwan Yook Byung Sik Kim Jung Shin Lee 《Clinical cancer research》2004,10(9):3076-3081
PURPOSE: Constitutive mutational activation of c-kit has been found to be associated with the pathogenesis of gastrointestinal stromal tumors (GISTs). The prognostic significance of c-kit mutations, however, is still controversial. EXPERIMENTAL DESIGN: We examined 86 patients curatively resected for localized GIST. Genomic DNA was extracted from paraffin-embedded tumor tissues. Exons 9, 11, 13, and 17 of the c-kit gene were amplified by PCR and sequenced. RESULTS: Mutations in exon 11 were detected in 61 tumors, and mutations in exon 9 were observed in three tumors, whereas no mutations were detected in exons 13 or 17. The overall c-kit mutation frequency was 74%. Amino acid alterations in the 61 tumors with exon 11 mutations were deletion in 33 tumors, substitution in 20, both deletion and substitution in 4, insertion in 1, and duplication in 3. Histologically, tumors with c-kit mutations showed higher mitotic counts and higher cellularity. The 5-year relapse-free survival (RFS) in patients having GISTs with c-kit mutations was 21%, compared with 60% in those without c-kit mutations. Significantly higher RFS rates were observed in patients with tumors having mitotic counts < 5 mitoses/50 high power field, spindle-cell histology, tumor size < 5 cm, or gastric GISTs. Multivariate analyses indicated association of poorer RFS with a higher mitotic count > or = 5 of 50 high power fields; odds ratio (OR) = 3.0], presence of c-kit mutations (OR = 5.6), and a larger tumor size (> or = 5 cm; OR = 4.2). CONCLUSIONS: The presence of c-kit mutation, along with high mitotic count and larger tumor size, was an independent factor for poor prognosis in patients with localized GISTs. 相似文献
999.
1000.